REFERENCES
1. Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875-88.
2. van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389:1778-89.
3. Hamidi H, Senbabaoglu Y, Beig N, et al. Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Cancer Cell. 2024;42:2098-2112.e4.
4. Seiler R, Ashab HAD, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72:544-54.
5. Singh P, D'Rozario R, Chakraborty B, et al. Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer. Nat Commun. 2026;17:1382.
6. Qiu H, Makarov V, Bolzenius JK, et al. KDM6A loss triggers an epigenetic switch that disrupts urothelial differentiation and drives cell proliferation in bladder cancer. Cancer Res. 2023;83:814-29.
7. Zhang D, Tang Z, Huang H, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574:575-80.
8. Kumagai S, Koyama S, Itahashi K, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40:201-218.e9.
9. Watson MJ, Vignali PDA, Mullett SJ, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591:645-51.
10. Li Y, Kang Z, Du Y. Beyond PD-1/PD-L1: new immune checkpoints and therapeutic combinations in cancer immunotherapy. Med Bull. 2026;2:61-93.
11. Wu Y, Liang J, Sun R, et al. Prognostic migrasome-associated long noncoding RNA model and tumor immune landscape in bladder cancer. J Cancer Metastasis Treat. 2026;12:8.
12. Sharma R, Malviya R. Modifying the electrical, optical, and magnetic properties of cancer cells: A comprehensive approach for cancer management. Med Adv. 2024;2:3-19.
13. Viehweger F, Gorbokon N, Büyücek S, et al. KDM6A expression loss is frequent in low grade non-invasive urothelial carcinomas of the urinary bladder. Pathologica. 2025;117:296-305.
14. Yang RK, Alvarez H, Lucas AS, et al. Microsatellite instability and high tumor mutational burden detected by next generation sequencing are concordant with loss of mismatch repair proteins by immunohistochemistry. Cancer Genet. 2025;290-291:44-50.
